0 0 0 0 0.013911620294599 0.0128232405891981 0.00736497545008182 0.0253682487725041

Stock impact report

INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer’s Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three Years

INmune Bio Inc. - Common stock (INMB)

Boca Raton, Florida, April 30, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, is pleased to share an update on two patients from the Phase 1b trial completed in 2021 who have continued to receive XPro™ for treatment of Alzheimer’s Disease (AD) for more than three years under the Australian compassionate use program known as the Special Access Scheme (SAS). Both patients, herein referred to as “Patient 1” and “Patient 2,” was an original study participant in the Phase 1b clinical trial (ClinicalTrials.gov ID NCT03943264), in the target dose 1mg/kg cohort, which commenced in November of 2019 and completed in September of 2021. In contrast to clinical trials, patients in the SAS receive exclusive care from their primary care physicians, with the Company's involvement limited to supplying XPro™. Reports from the primary Show less Read more

Download PDF

Impact Snapshot

Event Time:

INMB

Last Price

Price Change

Price Change%

Volume Shares

Max Up

Max Down

Volume Ratio

Performance Comparison Updated

Event Day Stock performance from the time of news release until the following 4pm ET market close	Last price at news event	Since Event Multi-day stock performance from the time of the news release
EVENT DAY Stock performance from the time of news release until the following 4pm ET market close	LAST PRICE AT NEWS EVENT	SINCE EVENT Multi-day stock performance from the time of the news release
	Last Price
	VWAP
High:	Max Up	High:
Low:	Max Down	Low:

%	Post news range	%
	Price change
	Price Change Percentage
	S&P 500 (SPX)
%	Volume ratio	%
	Volume
	Ticks
	Avg transaction size

Don't Miss Out On The Next BIG Stock Move

Event day

Event Day Chart will not be displayed beyond 90-day period of the event

Performance since event

Time And Velocity Analysis

Opt-in for INMB alerts

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer’s Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three Years

Opt in for alerts from News Quantifed

Opt in for alerts from News Quantifed

Opt in for alerts from News Quantifed

Opt in for alerts from News Quantifed

Opt in for alerts from News Quantifed